FTC Action. Good thing the IPIX drugs are based on real science and not crap like NNVC:
Quote:Marketers Barred from Making Deceptive Claims about Products’ Ability to Mitigate Side Effects of Cancer Treatment
CellMark and its CEO lacked scientific evidence to back up their products’ claims
For Release
January 11, 2018
Tags:
Bureau of Consumer Protection Consumer Protection Advertising and Marketing Health Claims
CellMark Biopharma, LLC and its CEO have agreed to settle Federal Trade Commission charges that they made false or unsupported claims regarding two health products they marketed as effective treatments for cancer patients’ malnutrition and “chemo fog,” or treatment-related cognitive dysfunction.
CellAssure package, with tagline 'Advanced Medical Nutrition'According to the Commission’s complaint, CellMark and its CEO, Derek E. Vest, violated the FTC Act by deceptively advertising two products for cancer patients: CellAssure, to treat cancer-related malnutrition, and Cognify, to treat “chemo fog.” A one-month supply of CellAssure sold for $248 and a one-month supply of Cognify sold for $79.
The FTC alleges that the defendants advertised the two products with a range of deceptive and unsupported health benefits for cancer patients. For example, the defendants described CellAssure as a medical breakthrough solution that “specifically addresses the malnutrition suffered by over 80% of all cancer patients” and claimed that CellAssure treats cancer with its “anti-cancer and anti-tumor properties.”
The defendants described Cognify as “the world’s first product designed specifically to alleviate . . . chemo fog . . . .” They also disseminated a YouTube video featuring a breast cancer patient who claimed that after taking Cognify, she could “remember the names of places and people and things” and started “thinking more clearly.” However, according to the FTC complaint, the defendants did not possess scientific evidence that these products provided any of the claimed benefits.
The proposed final stipulated order settling the Commission’s charges prohibits the defendants from engaging in similar conduct in the future. It requires them to have competent and reliable scientific evidence to support health claims for any product, and bars them from misrepresenting the results of any study, test, or scientific research.
The Commission vote authorizing the staff to file the complaint and proposed final stipulated order was 2-0. The FTC filed the documents in the U.S. District Court for the Middle District of Florida, Fort Myers Division.
NOTE: The Commission files a complaint when it has “reason to believe” that the law has been or is being violated and it appears to the Commission that a proceeding is in the public interest. Stipulated final injunctions/orders have the force of law when approved and signed by the District Court judge.
The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about consumer topics and file a consumer complaint online or by calling 1-877-FTC-HELP (382-4357). Like the FTC on Facebook (link is external), follow us on Twitter (link is external), read our blogs and subscribe to press releases for the latest FTC news and resources.
Contact Information
MEDIA CONTACT:
Mitchell J. Katz (link sends e-mail)
Office of Public Affairs
202-326-2161
STAFF CONTACT:
Carolyn L. Hann
Bureau of Consumer Protection
202-326-2745
3
